Overview We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low. We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of ap...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001672688-26-000068 | EDGAR | 83K words |
| 2025-03-18 | 2024-12-31 | 0001628280-25-013464 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001628280-24-012366 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001628280-23-009908 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001628280-22-006925 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001672688-25-000084 | EDGAR | 56K words |
| 2025-08-12 | 2025-06-30 | 0001628280-25-039938 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001628280-25-025077 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046862 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001628280-24-037193 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001628280-24-023062 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001628280-23-038983 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001628280-23-029197 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001628280-23-018165 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029092 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001628280-22-022331 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001628280-22-013760 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001672688-26-000066 | EDGAR | 3K words |
| 2026-03-06 | 0001672688-26-000047 | EDGAR | — |
| 2026-01-14 | 0001672688-26-000003 | EDGAR | — |
| 2025-11-12 | 0001672688-25-000082 | EDGAR | — |
| 2025-11-04 | 0001672688-25-000076 | EDGAR | — |
| 2025-08-12 | 0001628280-25-039878 | EDGAR | — |
| 2025-07-25 | 0001193125-25-165466 | EDGAR | — |
| 2025-07-08 | 0001628280-25-034544 | EDGAR | — |
| 2025-06-12 | 0001628280-25-030953 | EDGAR | — |
| 2025-05-13 | 0001628280-25-025075 | EDGAR | — |
89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001672688 |
| Ticker | ABSI |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Website | https://www.absci.com |
| Listed | 2021-07-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report